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Tazarotene, a member of the new class of acetylenic retinoids, has been shown to be effective in the treatment of
several hyperproliferative skin diseases, including non-melanoma skin cancer. Its effectiveness is thought to rely
on the ability to activate retinoic acid receptors b and c and to induce a number of downstream anti-proliferative
genes. Here, we show that the p53-related gene p73 is a target of tazarotene. Indeed, tazarotene modulates the
expression of the p73 gene in immortalized keratinocyte cell lines by inducing the pro-apoptotic and anti-prolif-
erative TAp73 isoforms and by repressing the anti-apoptotic and pro-proliferative DNp73 isoforms. This occurs at
the transcriptional level through a coordinated action on P1p73 and P2p73 promoters that control the expression of
TA and DN isoforms, respectively. The selective downregulation of DNp73 expression by small interfering RNA led
to an enhancement of tazarotene-induced bax activation and apoptosis, whereas the downregulation of both TA
and DN isoforms impairs tazarotene-mediated apoptosis. These results indicate the relevance of p73 gene products
in tazarotene-induced growth inhibition and effectiveness in the treatment of skin tumors.
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Retinoids modulate the growth and differentiation of cancer
cells presumably by activating gene transcription via the
nuclear retinoic acid receptor (RAR) a, b, and g and retinoid
X receptor (RXR) a, b, and g. Tazarotene is a retinoid whose
properties are the result of a rationale approach to drug
design (Duvic et al, 1997; Johnson and Chandraratna,
1999). Its molecular structure was engineered in such a way
as to be selective for the RAR class of nuclear receptors
over RXR, to activate RARb and RARg preferentially over
RARa and to possess clinically favorable pharmacokinetic
properties. Tazarotene, initially used to treat cutaneous
hyperproliferative conditions such as psoriasis (Marks,
1999) and ichtiosis (Stege et al, 1998; Hofmann et al,
1999), has subsequently been used with success in the
topical treatment of basal cell carcinomas (BCC) (Peris et al,
1999). The molecular mechanisms underlying the effective-
ness of this retinoid as anti-tumoral agent are unknown and
are thought to rely on its ability to modulate the expression
of a specific subset of genes leading to cell-cycle arrest,
differentiation, or apoptosis. The recently identified TIG1, 2,
and 3 genes (tazarotene-induced genes) are thought to
mediate at least some of the anti-tumoral activities of ta-
zarotene and have been found to be downregulated in some
tumors (Nagpal et al, 1996, 1997; Duvic et al, 2000). In ad-
dition, we have recently demonstrated that the treatment of
BCC with tazarotene induces higher levels of apoptosis in
the lesion that correlate with an increased expression of the
pro-apoptotic protein bax (Orlandi et al, 2004).
Members of the p53 family of tumor suppressor genes
(p53, p63, and p73) are the molecular targets of several anti-
cancer therapies and are thought to play a critical role in the
clinical outcome of chemotherapy through the induction of
apoptosis and cell-cycle arrest of cancer cells (Levrero et al,
2000; Flores et al, 2002; Zaika et al, 2002). The role of the
p53 family in the regulation of the cell response to retinoids
is still unclear. We therefore investigated the role of p53
family members in response to tazarotene treatment in
immortalized keratinocyte cell lines.
Both p73 and p63 exist as a group of full-length isoforms
that arise from alternative splicing at the C-terminus (TAp73
a–z) (De Laurenzi et al, 1999; Levrero et al, 2000; Dohn et al,
2001) and are all capable of inducing both cell-cycle arrest
and apoptosis when overexpressed. In addition, amino-ter-
minally truncated isoforms (DNp73s) that lack the transac-
tivation domain and exert a dominant-negative function
towards p53, p73, and p63 activity have been described
(Sayan et al, 2001). DNp73 is expressed in vivo in the de-
veloping brain where it counteracts p53-dependent apop-
tosis (Pozniak et al, 2000), and DNp73 isoforms are
overexpressed in a variety of human cancers but not in
normal tissues (Zaika et al, 2002). Similarly, truncated iso-
forms of the related protein p63 may act as dominant-neg-
ative inhibitors of p53- and p73-dependent transcription
(Yang et al, 1998), protect keratinocytes from UV-induced
apoptosis in vitro and in vivo (Liefer et al, 2000) and are
overexpressed in a number of epithelial tumors (Crook et al,
2000).
Abbreviations: FACS, fluorescence-activated cell sorting; RAR, re-
tinoic acid receptor; siRNA, small interfering RNA
Copyright r 2004 by The Society for Investigative Dermatology, Inc.
1162
Here, we show that tazarotene treatment of immortalized
keratinocytes induces the expression of the pro-apoptotic
TAp73b isoform and downregulates the anti-apoptotic
DNp73 isoforms through a coordinated action on two pro-
moters that involves the downregulation of AP-1 activity.
Moreover, we show that the selective ablation of DNp73
expression by small interfering RNA (siRNA) enhances ta-
zarotene-induced apoptosis, suggesting that it may con-
tribute to the resistance of immortalized keratinocytes to
anti-tumoral therapy.
Results
Tazarotene upregulates TAp73 but not p53 or DNp63
protein expression in immortalized keratinocytes We
analyzed the expression of p53, p73, and p63 proteins in
the mouse immortalized keratinocytes cell line C5N harbor-
ing a wild-type p53 gene (Brown and Balmain, 1995) before
and after treatment with either tazarotene or retinoic acid.
As shown in Fig 1A, tazarotene and retinoic acid treatment
has no effect on p63 and p53 expression, but induces
TAp73 expression as already observed in neuroblastoma
cell lines (De Laurenzi et al, 2000). In addition, a clear
downregulation of the DNp73 protein level is observed after
treatment. The majority of BCC harbor at least one mutated
p53 allele (Magal et al, 1998). To extend our observations to
keratinocytes carrying a mutated p53, we treated the hu-
man immortalized keratinocytes HaCaT cell line with in-
creasing concentrations of tazarotene. Similar to the results
obtained in C5N cells, a concentration-dependent induction
of the TAp73b protein, the isoform that is prevalent in both
the C5N and the HaCaT keratinocytes cell lines, and a re-
duction in DNp73a protein (Fig 1B and data not shown) are
observed, thus indicating that the mutational status of p53
does not influence tazarotene-induced p73 accumulation.
Tazarotene has opposite functions on TAp73 and DNp73
transcription TAp73 and DNp73 expression is regulated at
the transcriptional level through the usage of two different
promoters: the P1p73 (located upstream exon 1) and P2p73
promoter (located in intron 3). The P1p73 promoter controls
the expression of TAp73, whereas the P2p73 promoter reg-
ulates the transcription of DNp73 (Fig 2A). To evaluate the
effects of tazarotene on TAp73 and DNp73 transcription, we
analyzed the levels of TA and DN transcripts by semiquan-
titative RT-PCR. As shown in Fig 2B, treatment of HaCaT
cells with tazarotene induces the accumulation of TAp73
transcripts, whereas the amount of DNp73 is significantly
reduced in the same cells. The levels of DNp63 and p53
transcripts are not significantly modulated by tazarotene
treatment (data not shown). These results indicate that ta-
zarotene modulates the expression of the p73 gene by
inducing the transcription of the pro-apoptotic, anti-
proliferative TA isoforms and downregulating the anti-apo-
ptotic, proliferative DN isoforms.
To study the molecular mechanisms involved in the reg-
ulation of the p73 gene upon tazarotene treatment, we iso-
lated the genomic regions of the p73 gene containing the
P1p73 promoter and the P2p73 promoter and constructed
luciferase reporter plasmids (Vossio et al, 2002) (Fig 3A).
Sequence analysis of the P1p73 promoter revealed, in ad-
dition to multiple E2F binding sites, the presence of several
sequences containing putative RAR binding elements. We
transfected three deletion mutants of the P1p73-luc plasm-
ids and evaluated the transcriptional activity of these con-
structs in HaCaT cells by luciferase assay. Tazarotene
treatment of transfected cells induced a clear increase in
transcriptional activity of all deletion mutants tested (Fig
3B). Interestingly, both the basal activity and the levels of
induction of the 883 mutant, containing only one putative
RAR element, were significantly lower as compared with the
4000/þ 400 reporter constructs. These results suggest
Figure 1
Tazarotene (Taz) treatment induces TAp73
protein and downregulates DNp73. (A) C5N
cells were treated with 2 mM Taz or with 2 mM all-
trans-retinoic acid and lysed after 24 h. The lev-
els of endogenous p53, DNp63, p73, and DNp73
were analyzed by immunoblotting using specific
antibodies. An anti-actin immunoblot was per-
formed to ensure that equal amounts of proteins
were loaded. (B) HaCaT cells were left untreated
or were treated with increasing concentrations of
tazarotene for 24 h and lysed. Eighty micrograms
of total cell extract was analyzed by immuno-
blotting using anti-p73 or anti-p63 specific anti-
bodies.
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that the P1p73 promoter is a target of retinoid stimulation in
HaCaT cells.
Sequence analysis of the P2p73 promoter revealed, in
addition to the already known p53 responsive element, the
presence of a canonical AP-1 binding sequence (50-
TGAGTCAG-30) located between nt 455 and 462 of the
promoter (GeneBank Accession no. AB055067) (Fig 3C).
AP-1 is a protein complex comprised of c-Jun and c-Fos; it
mediates mitogenic signals, and its activation is associated
with increased cell proliferation (Angel et al, 2001). One way
in which RAR regulate the expression of certain genes is
thought to involve trans-repression of AP-1 activity (Altucci
and Gronemeyer, 2001). Many studies suggest that this ef-
fect may also mediate retinoid-induced growth inhibition
(Fanjul et al, 1994; Chen et al, 1995). Both retinoic acid and
tazarotene have been shown to be potent inhibitors of AP-1
activity (Nagpal et al, 1995).
We tested the ability of tazarotene to downregulate the
transcriptional activity of the P2p73 promoter in a luciferase
reporter assay. Interestingly, whereas the full-length pro-
moter (2500) is strongly repressed by the treatment with
tazarotene, the basal transcriptional activity of the 1400
and 593 constructs (lacking the AP-1 canonical site) is
lower and is not modulated by the treatment with tazaro-
tene, suggesting that the AP-1 activity may be required for
both the basal transcriptional activity and for the retinoid-
induced modulation of the P2p73 promoter in HaCaT cells
(Fig 3D). To further investigate the role of AP-1 in the reg-
ulation of P2p73 promoter in HaCaT cells, we cotransfected
the full-length (P2p73 2500 luc) reporter construct togeth-
er with the expression vectors that encode for c-Jun or for
the dominant-negative mutant of c-Jun that is still able to
bind the DNA but lacks the transactivation domain (c-Jun
D169).
The overexpression of c-Jun induces an increase of pro-
moter activity and does not impair the tazarotene-mediated
downregulation, whereas the overexpression of c-Jun D169
efficiently downregulates the basal activity of the P2p73
promoter and blocks any further downregulation mediated
by tazarotene (Fig 3E). These results suggest that the AP-1
activity is involved in the regulation of the P2p73 promoter in
both basal conditions and upon treatment with the b/g-se-
lective retinoid tazarotene.
Selective downregulation of DNp73 sensitizes HaCaT
cells to tazarotene-induced cell death Increasing evi-
dences indicate that DNp73 protein (whose transcription is
regulated by the P2p73 promoter) plays an important role in
the regulation of p53/p73-mediated responses following
DNA damage or other stressors (Levrero et al, 2000; Flores
et al, 2002; Vossio et al, 2002; Zaika et al, 2002). We have
recently shown that treatment of BCC with tazarotene cor-
relates in vivo with increased levels of RARb expression, bax
expression, and a higher apoptotic rate (Orlandi et al, 2004).
To evaluate the role of the p73 gene in tazarotene-
induced cell death, we selectively downregulated its tran-
scripts by small interfering RNA. RNA interference (RNAi) or
RNA silencing is the process whereby double-stranded
RNA induces a homology-dependent degradation of cog-
nate mRNA. Recently, small interfering RNA have been
shown to achieve a high degree of specificity with low tox-
icity in mammalian cells (Caplen et al, 2001; Elbashir et al,
2001) acting through a degradative chain reaction catalyzed
by the activation of a cellular RNA-dependent RNA polym-
erase (Lipardi et al, 2001; Sijen et al, 2001). HaCaT cells
were transfected with siRNA that target all the p73 tran-
scripts (p73 siRNA) (Vossio et al, 2002) or DNp73 (DNp73
siRNA) isoforms. Given the low transfection rate of HaCaT
Figure 2
Tazarotene (Taz) activates TAp73 and re-
presses DNp73 transcription. (A) Schematic
diagram representing the 50 portion of p73 gene
and its two gene products. The locations of the
P1p73 promoter (TA isoforms) and the P2p73
(DNp73 isoforms) are indicated by P1 and P2,
respectively. (B) Five micrograms of total mRNA
from HaCaT cells treated with the indicated con-
centrations of Taz for 24 h were subjected to re-
verse transcription using random hexamers.
One-tenth of the RT product was amplified in a
semiquantitative PCR using primers specific for
TAp73, DNp73, or actin (left panel). The relative
amount of TAp73 and DNp73 transcripts was
assessed by densitometric quantitation of PCR
bands (ImageQuant 2.1 software) after normal-
ization with actin. Results are expressed as rel-
ative expression after setting the untreated
samples as 100% (right panel).
1164 PAPOUTSAKI ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
cells, the efficacy of our siRNA in the specific downregu-
lation of their target transcripts was evaluated by transient
cotransfection experiments. As shown in Fig 4A, DNp73-
specific siRNA downregulate the exogenously expressed
HA-DNp73 but have no effect on the levels of HA-TAp73.
The p73 siRNA downregulates both TA and DN isoforms but
has no effect on the unrelated actin protein levels, confirm-
ing the specificity of the siRNA.
To determine the role of p73 in tazarotene-induced bax
activation, we performed transcriptional assays with a re-
porter plasmid containing the bax promoter. As shown in Fig
4B, treatment of HaCaT cells with tazarotene induces the
transcriptional activation of bax promoter. This induction,
however, is almost completely abrogated by the cot-
ransfection of p73-specific siRNA oligonucleotides, indicat-
ing the requirement of p73 for the upregulation of bax after
tazarotene treatment. As expected, the transfection of
DNp73-specific siRNA increased both the basal bax pro-
moter activity, and the tazarotene-induced activity, sug-
gesting that the TA/DNp73 ratio may play a role in the
regulation of tazarotene-mediated regulation of pro-apo-
ptotic genes.
The levels of apoptosis in untreated or tazarotene-treat-
ed cells were evaluated by fluorescence-activated cell sort-
ing (FACS) analysis. As shown in Fig 4C, the transfection of
the siRNA specific for p73 or DNp73 sensitizes the untreat-
ed HaCaT cells to apoptosis, indicating that the p73 path-
way may play an important role in the survival of HaCat
cells. FACS analysis also showed a sensitization to
apoptosis of DNp73 siRNA-transfected cells after tazaro-
tene treatment. Interestingly, cells transfected with pan-p73
siRNA did not show any significant increase in tazarotene-
mediated apoptosis, suggesting that the TAp73 isoforms
may be critical regulators of cell survival after tazarotene
treatment and may mediate apoptosis induced by tazaro-
tene.
Discussion
In view of the well-established effectiveness of retinoid
therapy in the treatment of several neoplastic diseases,
identification of molecular pathways involved in cellular re-
sponses to retinoids is thought to be of great help in setting
Figure 3
The P1p73 promoter is activated by tazarotene (Taz). (A) Schematic representation of the P1p73 promoter reporter plasmids. The presence of
putative retinoic acid receptor binding sites as well as E2F sites and TATA box is indicated. (B) HaCaT cells were transfected with 1 mg of the
indicated luciferase encoding reporter plasmid and with 50 ng of the Renilla encoding pRL-null plasmid. Eighteen hours after transfection, cells were
treated with tazarotene (2 mM) for 24 h. Cells were lysed and luciferase activity was quantified by the Dual Luciferase reporter kit (Promega Inc.).
Renilla activity was used to normalize the transfection efficiency. Results are expressed as luciferase activity relative to Renilla activity. Results
represent the mean of three independent experiments performed in duplicate. Error bars represent 1 standard deviation. (C) Schematic repre-
sentation of the P2p73 promoter reporter plasmids. (D) HaCaT cells were transfected with 1 mg of the indicated luciferase encoding reporter plasmid
and with 50 ng of the Renilla encoding pRL-null plasmid. Eighteen hours after transfection, cells were treated with tazarotene (2 mM) for 24 h.
Luciferase activity was measured as in Fig 3. (E) HaCaT cells were cotransfected with the 2500 P2p73 promoter and expression vectors encoding
for c-Jun or its mutant the c-Jun-D169. Eighteen hours after transfection, cells were left untreated or were treated with tazarotene 2 mM for 24 h, and
the luciferase activity was measured as described in Materials and Methods.
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up strategies to potentiate retinoid activity towards cancer
cells. In this paper, we evaluated the role of p53 family of
tumor suppressor genes in immortalized keratinocytes in
response of to a b/g-selective retinoid tazarotene. We found
that tazarotene treatment does not affect the levels of p53
and DNp63 proteins, which are thought to play a critical role
in the regulation of keratinocyte cell death following a wide
number of stimuli. Interestingly, the levels of the TAp73 pro-
tein are clearly increased by tazarotene treatment, whereas
we observed a strong reduction in the levels of DNp73 pro-
tein. A similar behavior has been observed in neuroblasto-
mas, where the p73 pathway plays a critical role in the
control of apoptosis and the levels of DNp73 have a high
prognostic value for the survival and the outcome of therapy
in patients affected by neuroblastoma (Casciano et al,
2002a, b). In agreement with these results, we observed that
both the increase in TAp73 and the downregulation of
DNp73 occur mainly at the transcriptional level. To better
characterize the molecular pathways involved in this mod-
ulation, we isolated the genomic region containing the
DNp73 promoter (P2p73 promoter), and found, by se-
quence analysis, the presence of a canonical AP-1 site. In-
terestingly, reporter constructs lacking this site display a low
transcriptional activity in HaCaT cells and the cotransfection
of a dominant-negative mutant of c-Jun strongly downreg-
ulates the activity of the full-length P2p73 promoter. These
results indicate that DNp73 is a target of AP-1 transcrip-
tion factors in immortalized keratinocytes, and that the
transcriptional repression of this promoter observed after
tazarotene treatment may be because of the retinoid-
mediated downregulation of AP-1 activity (Nagpal et al,
1995). AP-1 activity has been shown to be correlated to the
transformation status of keratinocytes, being low in primary
keratinocytes and progressively increasing together with the
c-Jun protein levels in the different steps of keratinocytes
transformation (Zoumpourlis et al, 2000). Our findings link
AP-1 activity to the expression of the proliferative and anti-
apoptotic protein DNp73. Furthermore, in order to under-
stand the physiological relevance of DNp73 in response to
tazarotene treatment, we modulated the expression of en-
dogenous p73 transcripts by using specific siRNA. The se-
lective downregulation of DNp73 led to an increase in the
transcriptional activity of the pro-apoptotic gene bax, which
correlates with a sensitization to tazarotene-induced apop-
tosis, whereas the downregulation of all p73 transcripts
(both TA and DN isoforms) resulted in resistance to tazaro-
tene treatment, strongly indicating the involvement of p73 in
the regulation of cellular response to tazarotene. Our find-
ings provide important information that will hopefully be
useful in setting up new therapeutical approaches (e.g.
DNp73-specific siRNA) to potentiate retinoids anti-tumoral
activity.
Materials and Methods
Cell lines C5N (a kind gift from Byron Han and Allan Balmain from
UCSF, San Francisco, California) and HaCaT cells lines were grown
in monolayer culture in Dulbecco’s modified Eagle’s medium con-
taining 10% regular fetal bovine serum and antibiotics at 371C in a
humidified atmosphere composed of 95% air and 5% CO2.
Retinoids Tazarotene (AGN 190168; ethyl 6-[2-(4,4-di-methyl-
thiochroman-6-yl)-ethynyl] nicotinate), an RARb/g-selective retinoid,
Figure 4
P73 gene products regulate the sensitivity of HaCat cells to tazarotene-induced cell death. (A) HaCat cells were transfected with 1 mg of an
expression vector encoding for green fluorescent protein (GFP)–spectrin fusion protein together with 2 mg of the indicated expression vector and 5
mg of p73- or DNp73-specific small interfering RNA (siRNA). thirty-six hours after transfection, the expression of HAp73 or HA-DNp73 was evaluated
by immunoblotting. Actin expression was used as loading and specificity control. (B) HaCaT cells were transfected with 0.5 mg of the bax-luc
reporter plasmid, 50 mg of the pRL-null plasmid, and 1 mg of the indicated siRNA. The day after transfection, cells were treated with 2 mM tazarotene
for 24 h and luciferase activity was determined as described in Materials and Methods. Results represent the mean of three experiments in
duplicate. Error bars represent 1 SD. (C) HaCat cells were transfected with 1 mg of an expression vector encoding for GFP–spectrin fusion protein
and 5 mg of the indicated siRNA. Eighteen hours after transfection, cells were mock treated or were treated with 2 mM tazarotene for 24 h. Cells were
then harvested, stained with propidium iodide, and GFP expressing cells were evaluated for their DNA content by fluorescence-activated cell sorting
analysis as described in Materials and Methods. Results express the percentage of cells with sub-G1 content of DNA and are representative of three
independent experiments.
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was synthesized in the Department of Chemistry, Retinoid Re-
search, Allergan (Irvine, California). All-trans-retinoic acid (RA) was
purchased from Sigma (Sigma-Aldrich, St. Louis, Missouri).
Antibodies and immunoblotting Antibodies directed against ac-
tin, p63 (4A4 clone) and p53 (FL-393), were purchased from Santa
Cruz Biotechnology Inc (Santa Cruz, California). The mouse mono-
clonal anti-p73 antibody (clone 1288) (Imgenex Inc., San Diego,
California) recognizes all the known alternative splicing variants of
the human and mouse p73 (Costanzo et al, 2002). The mouse
monoclonal anti-DNp73 antibody (Imgenex Inc.) recognizes only
the DNp73 variants. Immunoblotting assays were performed es-
sentially as described (Costanzo et al, 2002). Cells were lysed in
50 mM Tris, pH 8, 120 mM NaCl, and 0.5% NP-40, and protein
concentration was determined by the BioRad (Irvine, California)
dye-binding assay. Fifty to 100 mg of total cell extract was loaded
on denaturing SDS-PAGE and blotted onto a polyvinylidene diflu-
oride membrane. Western blot analysis was performed with the aid
of the enhanced chemiluminescence system (Amersham Pharma-
cia Biotech Inc. Uppsala, Sweden).
Reporter plasmids, transient transfections, and luciferase as-
say The P1p73luc-3500, P1p73luc-1400, P1p73luc-883, P2p73luc-
2500, P2p73luc-1400, and P2p73luc-593 reporter plasmids were
constructed by inserting a PCR-amplified fragment of the p73 gene
into SmaI site of the luciferase expressing pGL3 plasmid (Promega
Inc., Madison, Wisconcin). All constructs were verified by se-
quencing analysis. The bax-luc reporter vector has already been
described (Vossio et al, 2002). pRL-null plasmid encoding renilla
luciferase was purchased from Promega. Cells were seeded in six-
well plates and cotransfected with pRL-null plasmid using Lip-
ofectamine Plus transfection reagent (Invitrogen Inc., Carlsbad,
California) following the manufacturer’s protocol. Luciferase activity
was determined using Dual-Luciferase Assay System (Promega)
using a luminometer. Results are expressed as relative luciferase
activity after normalization with Renilla activity each experiment was
performed in triplicate. The CMVc-Jun and CMVc-JunD169 expres-
sion plasmids were obtained from Dr Michael Karin (UCSD, La Jolla,
California). The expression vectors encoding for HA-tagged p73a
and DNp73a have already been described (Vossio et al, 2002).
RT-PCR RNA was isolated by the single step guanidinium is-
othiocyanate-phenol method as previously described (Costanzo
et al, 2002). Five micrograms of total RNA were reverse transcribed
with the first-strand cDNA syntesis kit (Amersham Pharmacia
Biotech Inc.). One-tenth of the reverse transcribed material was
used in PCR reactions. TAp73 transcript was amplified using prim-
ers F1 50-CCAAGTTCTCTGCTTTC-30 and R1 50-AGCTGAGCT-
CAAATGCTGAC-30. DNp73 transcript was amplified with primers
S1 50-AGTGGACAGCGAGCAGCTGAGC-30 and AS1 50-GCAGCA-
GAGCAGGTGAGGTGC-30. The actin transcript was amplified with
the following primers: human b-actin S primer: 50-CAAGAGA-
TGGCCACGGCTGCT-30; human b-actin A primer: 50-TCCTT-
CTGCATCCTGTCGGCA-30. The amount of amplified products
relative to actin expression was quantified by ImageQuant 2 soft-
ware (Molecular Dynamics, Krefeld, Germany).
siRNA siRNA specific for either p73 or DNp73 (Xeragon Inc.,
Huntsville, Alabama) were transfected using the Lipofectamine-
Plus reagent (Invitrogen Inc.) according to the protocol developed
by Caplen et al (2001). The pan-p73 siRNA was designed to tar-
get all the mouse and human p73 isoforms. The DNp73-specific
siRNA was designed to target only the DN isoforms of p73. The
sequences of the siRNA are:
siRNA p73 sense 50-CCAUCCUGUACAACUUCAUGU G-30,
siRNA p73 antisense 50-CAUGAAGUUGUACAGGAUGGU G-30,
siRNA DNp73 sense 50-CGUCGGUGACCCCGCACGGUU-30,
siRNA DNp73 antisense 50-CCGUGCGGGGUCACCGACGUU-30.
FACS analysis Apoptosis was assessed by FACS to determine
the fraction of cells with a sub-G1 content. HaCat cells were cot-
ransfected with an expression vector for green fluorescent protein
(GFP)–spectrin fusion protein together with the indicated siRNA.
Twenty-four hours after tazarotene treatment, the cells were har-
vested with 0.1% EDTA, fixed in ethanol, and stained with prop-
idium iodide. GFP-positive cells were gated using the Cell Quest
program, and the fraction of these cells with sub-G1 DNA content
was determined.
This work is dedicated to the memory of Andrea Pocci: a friend, a man
who fought cancer. We thank Prof. Carlo Pincelli, Dr Alessandra Mar-
coni, and Dr Giovanni Blandino for critically reading the paper. This
work was supported by grants from Italian Ministry of Health (Progetti
Finalizzati) and AIRC to A. C.
DOI: 10.1111/j.0022-202X.2004.23498.x
Manuscript received April 15, 2004; revised May 18, 2004; accepted
for publication July 26, 2004
Address correspondence to: Antonio Costanzo, MD, Department of
Dermatology, University of Rome ‘‘Tor Vergata’’, Viale Oxford 81, 00133
Rome, Italy. Email: antonio.costanzo@uniroma2.it, acostanzo2000@
yahoo.it
References
Altucci L, Gronemeyer H: The promise of retinoids to fight against cancer. Nat
Rev Cancer 1:181–193, 2001
Angel P, Szabowski A, Schorpp-Kistner M: Function and regulation of AP-1 sub-
units in skin physiology and pathology. Oncogene 20:2413–2423, 2001
Brown K, Balmain A: Transgenic mice and squamous multistage skin carcino-
genesis. Cancer Metastasis Rev 14:113–124, 1995
Caplen NJ, Parrish S, Imani F, Fire A, Morgan RA: Specific inhibition of gene
expression by small double-stranded RNAs in invertebrate and vertebrate
systems. Proc Natl Acad Sci USA 98:9742–9747, 2001
Casciano I, Banelli B, Croce M, et al: Role of methylation in the control of Del-
taNp73 expression in neuroblastoma. Cell Death Differ 9:343–345, 2002a
Casciano I, Mazzocco K, Boni L, et al: Expression of DeltaNp73 is a molecular
marker for adverse outcome in neuroblastoma patients. Cell Death Differ
9:246–251, 2002b
Chen JY, Penco S, Ostrowski J, et al: RAR-specific agonist/antagonists which
dissociate transactivation and AP1 transrepression inhibit anchorage-in-
dependent cell proliferation. EMBO J 14:1187–1197, 1995
Costanzo A, Merlo P, Pediconi N, et al: DNA damage-dependent acetylation of
p73 dictates the selective activation of apoptotic target genes. Mol Cell
9:175–186, 2002
Crook T, Nicholls JM, Brooks L, O’Nions J, Allday MJ: High level expression of
deltaN-p63: A mechanism for the inactivation of p53 in undifferentiated
nasopharyngeal carcinoma (NPC)? Oncogene 19:3439–3444, 2000
De Laurenzi VD, Catani MV, Terrinoni A, et al: Additional complexity in p73: In-
duction by mitogens in lymphoid cells and identification of two new
splicing variants epsilon and zeta. Cell Death Differ 6:389–390, 1999
De Laurenzi V, Raschella G, Barcaroli D, et al: Induction of neuronal differentiation
by p73 in a neuroblastoma cell line. J Biol Chem 275:15226–15231, 2000
Dohn M, Zhang S, Chen X: p63alpha and DeltaNp63alpha can induce cell cycle
arrest and apoptosis and differentially regulate p53 target genes. Onco-
gene 20:3193–3205, 2001
Duvic M, Helekar B, Schulz C, et al: Expression of a retinoid-inducible tumor
suppressor, tazarotene-inducible gene-3, is decreased in psoriasis and
skin cancer. Clin Cancer Res 6:3249–3259, 2000
Duvic M, Nagpal S, Asano AT, Chandraratna RA: Molecular mechanisms of ta-
zarotene action in psoriasis. J Am Acad Dermatol 37:S18–S24, 1997
Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T: Duplexes of
21-nucleotide RNAs mediate RNA interference in cultured mammalian
cells. Nature 411:494–498, 2001
Fanjul A, Dawson MI, Hobbs PD, et al: A new class of retinoids with selective
inhibition of AP-1 inhibits proliferation. Nature 372:107–111, 1994
Flores ER, Tsai KY, Crowley D, Sengupta S, Yang A, McKeon F, Jacks T: p63 and
p73 are required for p53-dependent apoptosis in response to DNA dam-
age. Nature 416:560–564, 2002
Hofmann B, Stege H, Ruzicka T, Lehmann P: Effect of topical tazarotene in the
treatment of congenital ichthyoses. Br J Dermatol 141:642–646, 1999
Johnson A, Chandraratna RA: Novel retinoids with receptor selectivity and func-
tional selectivity. Br J Dermatol 140 (Suppl. 54):12–17, 1999
TAZAROTENE REGULATES THE p73 GENE 1167123 : 6 DECEMBER 2004
Levrero M, De Laurenzi V, Costanzo A, Gong J, Wang JY, Melino G: The p53/p63/
p73 family of transcription factors: Overlapping and distinct functions.
J Cell Sci 113:1661–1670, 2000
Liefer KM, Koster MI, Wang XJ, Yang A, McKeon F, Roop DR: Down-regulation
of p63 is required for epidermal UV-B-induced apoptosis. Cancer Res
60:4016–4020, 2000
Lipardi C, Wei Q, Paterson BM: RNAi as random degradative PCR: siRNA primers
convert mRNA into dsRNAs that are degraded to generate new siRNAs.
Cell 107:297–307, 2001
Magal SS, Jackman A, Pei XF, Schlegel R, Sherman L: Induction of apopto-
sis in human keratinocytes containing mutated p53 alleles and its
inhibition by both the E6 e E7 oncoproteins. Int J Cancer 75:96–104,
1998
Marks R: The role of tazarotene in the treatment of psoriasis. Br J Dermatol 140
(Suppl. 54):24–28, 1999
Nagpal S, Athanikar J, Chandraratna RA: Separation of transactivation and AP1
antagonism functions of retinoic acid receptor alpha. J Biol Chem 270:
923–927, 1995
Nagpal S, Patel S, Asano AT, Johnson AT, Duvic M, Chandraratna RA: Tazaro-
tene-induced gene 1 (TIG1), a novel retinoic acid receptor-responsive
gene in skin. J Invest Dermatol 106:269–274, 1996
Nagpal S, Patel S, Jacobe H, et al: Tazarotene-induced gene 2 (TIG2), a
novel retinoid-responsive gene in skin. J Invest Dermatol 109:91–95,
1997
Orlandi A, Bianchi L, Costanzo A, Campione G, Spagnoli LG, Chimenti S: Ev-
idence of increased apoptosis and reduced proliferation in BCC treated
with tazarotene. J Invest Dermatol 122:1037–1041, 2004
Peris K, Fargnoli MC, Chimenti S: Preliminary observations on the use of topical
tazarotene to treat basal-cell carcinoma. N Engl J Med 341:1767–1768,
1999
Pozniak CD, Radinovic S, Yang A, McKeon F, Kaplan DR, Miller FD: An anti-
apoptotic role for the p53 family member, p73, during developmental
neuron death. Science 289:304–306, 2000
Sayan AE, Sayan BS, Findikli N, Ozturk M: Acquired expression of transcrip-
tionally active p73 in hepatocellular carcinoma cells. Oncogene 20:5111–
5117, 2001
Sijen T, Fleenor J, Simmer F, et al: On the role of RNA amplification in dsRNA-
triggered gene silencing. Cell 107:465–476, 2001
Stege H, Hofmann B, Ruzicka T, Lehmann P: Topical application of tazarotene in
the treatment of nonerythrodermic lamellar ichthyosis. Arch Dermatol
134:640, 1998
Vossio S, Palescandolo E, Pediconi N, Moretti F, Balsano C, Levrero M, Costanzo
A: DN-p73 is activated after DNA damage in a p53-dependent manner to
regulate p53-induced cell cycle arrest. Oncogene 21:3796–3803, 2002
Yang A, Kaghad M, Wang Y, et al: p63, a p53 homolog at 3q27–29, encodes
multiple products with transactivating, death-inducing, and dominant-
negative activities. Mol Cell 2:305–316, 1998
Zaika AI, Slade N, Erster SH, et al: DeltaNp73, a dominant-negative inhibitor of
wild-type p53 and TAp73, is up-regulated in human tumors. J Exp Med
196:765–780, 2002
Zoumpourlis V, Papassava P, Linardopoulos S, Gillespie D, Balmain A, Pintzas A:
High levels of phosphorylated c-Jun, Fra-1, Fra-2 and ATF-2 proteins
correlate with malignant phenotypes in the multistage mouse skin car-
cinogenesis model. Oncogene 19:4011–4021, 2000
1168 PAPOUTSAKI ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
